Insmed to Present at Three June Conferences
June 07 2018 - 8:00AM
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical
company focused on the unmet needs of patients with rare diseases,
today announced that management will present at the following
investor conferences:
- The Nasdaq 38th Investor Conference in London, on Tuesday, June
12, 2018 at 1:30 p.m. ET.
- The Goldman Sachs 39th Annual Global Healthcare Conference in
Rancho Palos Verdes, on Wednesday, June 13, 2018 at 1:40 p.m.
ET.
- The JMP Securities Life Sciences Conference in New York City on
Wednesday, June 20, 2018 at 3:00 p.m. ET.
The presentations will be webcast live and can be accessed by
visiting the investor relations section of the company's website
at www.insmed.com. The webcasts will be archived for a period
of 90 days following the conclusion of each live event.
About Insmed
Insmed Incorporated is a global biopharmaceutical company
focused on the unmet needs of patients with rare diseases. The
Company’s lead product candidate is ALIS, which is in late-state
development for adult patients with treatment refractory NTM lung
disease caused by MAC, which is a rare and often chronic infection
that is capable of causing irreversible lung damage and can be
fatal. Insmed's earlier-stage clinical pipeline includes
INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase
1 with therapeutic potential in non-cystic fibrosis bronchiectasis
and other inflammatory diseases, and INS1009, an inhaled
nanoparticle formulation of a treprostinil prodrug that may offer a
differentiated product profile for rare pulmonary disorders,
including pulmonary arterial hypertension. For more
information, visit www.insmed.com.
Contact:Blaine Davis Insmed Incorporated (908) 947-2841
blaine.davis@insmed.com
Insmed (NASDAQ:INSM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Insmed (NASDAQ:INSM)
Historical Stock Chart
From Sep 2023 to Sep 2024